Top

Neurological Sciences

Published in:

01-04-2019 | Torticollis Spasticus | Original Article

Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives

Authors: Dursun Ceylan, Sevda Erer, Mehmet Zarifoğlu, Nevin Türkeş, Güven Özkaya

Published in: Neurological Sciences | Issue 4/2019

Abstract

Objective

In this study, quality of life and psychiatric comorbid disorders were investigated in patients with cervical dystonia and their spouses and we also investigated the effect of botulinum toxin (BTX) treatment on these parameters.

Material and method

Thirty patients with cervical dystonia (CD) on BTX treatment and their spouses (n = 30) were included. Beck Depression Scale (BDS), State-Trait Anxiety Inventory I and II (STAI-I, STAI-II), Hospital Anxiety Scale (HAS), Hospital Depression Scale (HDS) for psychiatric comorbid disease assessment, Toronto Western Spasmodic Torticollis Scale (TWSTRS) for disease activity assessment, and Craniocervical Dystonia Questionnaire (CDQ-24), Cervical Dystonia Impact Profile (CDIP-58), and Short Form 36 (SF-36) questionnaires for quality of life assessment were used. BDS, STAI-I and STAI-II, HAS, HDS, and SF-36 scales were also obtained from the spouses. The same tests were applied both before and 8 weeks after the BTX treatment.

Conclusion

In our study, an increase in psychiatric comorbid disorders such as depression and anxiety was observed and the quality of life was adversely affected in all areas in patients. In the spouses of the patients, the rates of psychiatric comorbid disorders such as depression and anxiety were found to be increased when compared to healthy subjects while vitality, mental health, and general health perception were found to be negatively affected.

Patients showed improvements in anxiety level, disease activity, and overall quality of life scales after BTX treatment.

Zurowski M, McDonald WM, Fox S, Marsh L (2013) Psychiatric comorbidities in dystonia: emerging concepts. Mov Disord 28. https://doi.org/10.1002/mds.25501

Fitzpatrick R (1992) “Quality of Life Measures in Health Care”, Applications and Issues in Assessement. BMJ 305:1074–1077CrossRefPubMedPubMedCentral

Page D, Butler A, Jahanshahi M (2007) Quality of life in focal, segmental and generalized dystonia. Mov Disord 23(3):341–347CrossRef

Queiroz MR, Chien HF, Barbosa ER (2011) Quality of life in individuals with cervical dystonia before botulinum toxin injection in a Brazilian tertiary care hospital. Arq Neuropsiquiatr 69:900–904CrossRefPubMed

Ben-Shlomo Y, Camfield L, Warner T, on behalf of the ESDE collaborative group (2002) What are the determinants of quality of life in people with cervical dystonia. J Neurol Neurosurg Psychiatry 72:608–614CrossRefPubMedPubMedCentral

Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, Kostic VS (2009) Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 111:161–164CrossRefPubMed

Stamelou M, Edwards MJ, Hallett M, Bathia KP (2012) The non -motor syndrome of primary dystonıyia: clinical and pathophysiological implications. Brain 135:1668–1681CrossRefPubMed

Akın YA, Akbostanci C, Mercan N, Aksun Z, Sorgun M (2012) Retrospective evaluation of 118 cervical dystonic cases treated with botulinum toxin Turk. J Neurol 18(3):104–107

Jog M, Chouinard S, Hobson D et al (2011) Causes for treatment delays in dystonia and Hemifacial spasm: a Canadian SurveyCan. J Neurol Sci 38:704–711CrossRef

10.

Tomic S, Petkovic I, Pucic T, Resan B et al (2016) Cervical dystonia and quality of life. Acta Neurol Belg 116:589–592CrossRefPubMed

11.

Slawek J, Friedman A, Potulska A et al (2007) Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type a injections. Functl Neurol 22:95–100

12.

Moraru E, Schnider P, Wimmer A, Wenzel T, Birner P, Griengl H et al (2002) Relation between depression and anxiety in dystonic patients: implications for clinical management. Depress Anxiety 16:100–103CrossRefPubMed

13.

Muller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W (2002) The Austrian botulinum toxin and dystonia study group. The impact of blepharospasm and cervical dystonia on health related quality of life and depression. J Neurol 249:842–846CrossRefPubMed

14.

Fabbri M, Superbo M, Defazio G, Scaglione CLM, Antelmi E, Basini G, Nassetti S, Pizza F, Plasmati R, Liguori R (2014) Quality of life in patients with craniocervical dystonia: Italian validation of the “cervical dystonia impact profile(CDIP-58)” and the “Craniocervical dystonia questionnaire (CDQ-24) ”. Neurol Sci 35:1053–1058CrossRefPubMed

15.

Lim VK (2007) Health related quality of life in patients with dystonia and tehir caregivers in new Zeland and Australia. Mov Disord 22(7):998–1003CrossRefPubMed

16.

Wollmer MA, Boer C, Kalak N et al (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 46:574–581CrossRefPubMed

17.

Kocaman G, Baslo MH, Hanağası H, Parman Y. İdyopatik servikal distonili hastalarda botulinum toksini uygulanmasından önce ve sonra kas aktivasyon paterninde görülen değişimlerin incelenmesi Nöropsikiyatri Arflivi 2009; 46: 39–43

18.

Fabbrini G, Berardelli I, Moretti G, Pasquini M, Bloise M, Colosimo C et al (2010) Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov Disord 25:459–465CrossRefPubMed

19.

Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J (2013) An open label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin a (Dysport). BMJ Open 3:e0011853. https://doi.org/10.1136/bmjopen-2012-001853 CrossRef

20.

Jen MH, Kurth H (2014) Assessing the burden of illness from cervical dystonia using the Toronto Western spasmodic torticollis rating scale scores and health utility: a meta- analysis of baseline patient-level clinical trial data. J Med Econ 17(11):803–809CrossRefPubMed

Title: Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives
Authors: Dursun Ceylan
Sevda Erer
Mehmet Zarifoğlu
Nevin Türkeş
Güven Özkaya
Publication date: 01-04-2019
Publisher: Springer International Publishing
Keywords: Torticollis Spasticus
Dystonia
Mood Disorders
Affective Disorder
Botulinum Toxin
Anxiety
Published in: Neurological Sciences / Issue 4/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-3719-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives

Abstract

Objective

Material and method

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Material and method

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2019

Characteristics of obstructive sleep apnea in myasthenia gravis patients: a single center study

Protective effects of CX3CR1 on autoimmune inflammation in a chronic EAE model for MS through modulation of antigen-presenting cell-related molecular MHC-II and its regulators

Predicting cerebral edema in ischemic stroke patients

A case report of Fisher syndrome with the detection of anti-GM3 and anti-GD1b IgG antibodies

The imaging features of cerebral septic infarction in two patients with infective endocarditis

Subcortical axonal loss with glial reactions following partial status epilepticus with neuroradiological findings of reduced subcortical diffusion